Hypothesis

Low-dose psilocybin microdosing accelerates fear extinction in PTSD by triggering a transient IL-6–dependent microglial activation state that promotes hippocampal synaptic remodeling, a process that can be distinguished from SSRI treatment by its rapid onset and reliance on 5-HT2A‑mediated downstream signaling.

Mechanistic Rationale

Psilocybin’s acute agonist action at 5-HT2A receptors induces cortical glutamate release and BDNF expression, leading to increased synaptogenesis (see [1]). In animal PTSD models, this translates into rescued dendritic complexity and spine density that underlie improved fear extinction ([2]). While serum BDNF fails as a reliable peripheral marker in humans ([3]), emerging data suggest that psychedelics modulate peripheral inflammatory cytokines, particularly IL-6, which can act as a neuromodulator of microglial phenotype and synaptic pruning ([4]). We propose that a brief IL-6 surge after each microdose primes microglia to a pro-plasticity state, facilitating the removal of perineuronal nets and the insertion of AMPA receptors, thereby strengthening extinction circuits. This mechanism diverges from SSRIs, which gradually increase extracellular serotonin without triggering the same IL-6 microglial cascade and therefore show slower structural changes.

Testable Predictions

1. In a within‑subject, double‑blind crossover trial, participants receiving psilocybin microdoses (e.g., 0.5 g dried mushrooms every third day) will show a significant rise in finger‑prick dried blood spot IL-6 levels 2–4 h post‑dose, peaking before the return to baseline at 24 h, whereas the SSRI arm will exhibit no IL-6 change.
2. Concurrent quantitative EEG will reveal increased theta-gamma coupling in the hippocampus-prefrontal network during extinction recall, observable within the first week of microdosing and correlating with the IL-6 peak magnitude.
3. Behavioral performance on a reversal-learning task will improve faster in the psilocybin group than in the SSRI group, with mediation analysis indicating that IL-6 change accounts for ≥30 % of the variance in extinction speed.
4. Blocking IL-6 signaling with a single subcutaneous dose of an anti-IL-6 receptor antibody prior to microdosing will abolish the EEG and behavioral benefits, confirming cytokine necessity.
5. Structural MRI hippocampal volumetry will show no significant difference between groups after four weeks, indicating that functional changes precede gross morphological alterations.

Methods Outline

• Recruit 60 PTSD patients (CAPS-5 ≥ 30) and randomize to psilocybin microdose, SSRI (sertraline 50 mg daily), or placebo, stratified by baseline IL-6.
• Collect finger-prick dried blood spots at 0, 2, 4, 8, 24 h after each dose for IL-6 and TNF-α ELISA.
• Acquire resting-state quantitative EEG (64‑channel) pre-dose and 2 h post‑dose on days 1, 3, 7; compute phase-locking value between hippocampal theta (4‑8 Hz) and prefrontal gamma (30‑50 Hz) sources via beamforming.
• Administer a computerized reversal-learning task twice weekly; calculate win-stay/lose‑shift ratios.
• Conduct CAPS-5 assessment at baseline, week 2, week 4.
• In a subsample (n = 15 per arm), administer anti‑IL‑6R (tocilizumab 8 mg/kg) or IgG control 30 min before the third microdose to test necessity.
• Analyze mixed-effects models for IL-6 trajectories, EEG coupling, and task performance; test mediation with bootstrapped indirect effects.

If the IL-6 surge and its correlation with rapid EEG and behavioral changes are observed only in the psilocybin arm and are abolished by IL-6 blockade, the hypothesis is supported. Absence of these patterns would falsify the proposed cytokine-mediated mechanism and suggest that psilocybin’s effects rely on alternative pathways.